IL270355B1 - - Google Patents

Info

Publication number
IL270355B1
IL270355B1 IL27035519A IL27035519A IL270355B1 IL 270355 B1 IL270355 B1 IL 270355B1 IL 27035519 A IL27035519 A IL 27035519A IL 27035519 A IL27035519 A IL 27035519A IL 270355 B1 IL270355 B1 IL 270355B1
Authority
IL
Israel
Application number
IL27035519A
Other languages
English (en)
Other versions
IL270355A (https=
IL270355B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270355A publication Critical patent/IL270355A/en
Publication of IL270355B1 publication Critical patent/IL270355B1/en
Publication of IL270355B2 publication Critical patent/IL270355B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL270355A 2017-05-15 2019-10-31 Treatment of multiple sclerosis using long-acting glatiramer and stem cells derived from adipose tissue IL270355B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2017/050535 WO2018211486A1 (en) 2017-05-15 2017-05-15 Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells

Publications (3)

Publication Number Publication Date
IL270355A IL270355A (https=) 2019-12-31
IL270355B1 true IL270355B1 (https=) 2023-02-01
IL270355B2 IL270355B2 (en) 2023-06-01

Family

ID=64273438

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270355A IL270355B2 (en) 2017-05-15 2019-10-31 Treatment of multiple sclerosis using long-acting glatiramer and stem cells derived from adipose tissue

Country Status (8)

Country Link
US (1) US11413311B2 (https=)
EP (1) EP3624815A4 (https=)
JP (1) JP7000458B2 (https=)
CN (1) CN110709091A (https=)
AU (1) AU2017414803B2 (https=)
CA (1) CA3062964C (https=)
IL (1) IL270355B2 (https=)
WO (1) WO2018211486A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
PT1248643E (pt) 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
AU2005308396B2 (en) * 2004-11-29 2011-06-09 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
WO2008057443A2 (en) 2006-11-03 2008-05-15 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
WO2011041240A1 (en) 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
US8481253B2 (en) 2008-03-19 2013-07-09 Cryo-Save Ag Cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
CN102186968A (zh) 2008-10-17 2011-09-14 巴克斯特国际公司 从脂肪组织获得细胞群的方法
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
CA2767300C (en) 2009-07-09 2020-01-07 Cellerix Sa Methods and compositions for use in cellular therapies
US8377885B2 (en) * 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP5916622B2 (ja) * 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
EP3351625A1 (en) 2010-02-18 2018-07-25 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible amniotic membrane products
KR20190114045A (ko) * 2010-12-17 2019-10-08 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
DK2744892T3 (en) 2011-09-23 2019-04-23 Cell Ideas Pty Ltd THERAPEUTICS USING FAT CELLS AND CELL SECRETIONS
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
EP2825638A4 (en) 2012-03-12 2015-11-25 Univ Singapore GENERATION OF BROWN FAT FABRIC FROM MESENCYCLES
TWI642781B (zh) 2014-02-06 2018-12-01 仲恩生醫科技股份有限公司 具優異細胞保護及免疫調節之quadri-正之基質細胞
WO2015120388A1 (en) 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CN109072189A (zh) 2016-02-12 2018-12-21 细胞治疗药物公司 脂肪组织衍生的间充质基质细胞条件培养基及其制备和使用方法
US12161688B2 (en) * 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
AU2018270396B2 (en) * 2017-05-15 2025-03-20 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Also Published As

Publication number Publication date
JP2020519658A (ja) 2020-07-02
EP3624815A1 (en) 2020-03-25
US11413311B2 (en) 2022-08-16
JP7000458B2 (ja) 2022-02-10
IL270355A (https=) 2019-12-31
US20200147141A1 (en) 2020-05-14
EP3624815A4 (en) 2021-01-20
CA3062964A1 (en) 2018-11-22
IL270355B2 (en) 2023-06-01
CA3062964C (en) 2024-11-12
AU2017414803A1 (en) 2019-12-05
WO2018211486A1 (en) 2018-11-22
CN110709091A (zh) 2020-01-17
AU2017414803B2 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
BR112019008823A2 (https=)
BR112020006084A8 (https=)
IL269893A (https=)
IL270355B1 (https=)
BR202018014992U2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)
BR202017010373U2 (https=)
BR202017009870U2 (https=)
BR202017006953U2 (https=)
CN303943982S8 (https=)
CN303795867S9 (https=)
CN303993627S (https=)
CN303949240S9 (https=)
CN303948614S9 (https=)
CN303892650S8 (https=)
CN303931240S8 (https=)